Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2895-2900

  Minato, Akinori ^a   Fujimoto, Naohiro ^a   Kubo, Tatsuhiko ^a   Harada, Shuji ^b   Akasaka, Soichiro ^c   Matsumoto, Tetsuro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Shinyukuhashi Hospital   (Japan)

^c Moji Medical Center Japan   (Japan)

Author keywords

Castration resistant prostate cancer; Estramustine phosphate; Risk classification; Survival

Indexed keywords

ESTRAMUSTINE PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84867978833     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0178-z     Document Type: Article

References (22)

1. Smaletz O, Scher HI, Small EJ, Verval DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-8.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med. 2004;351:1502-12.
3. Petrylak DP, Tangen CM, Hussain MH, Lura PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-5.
5. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80.
6. Mohler J, Bahnson RR, Boston B, Busby JE, D'amico A, Easthan JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw. 2010;8:162-200.
7. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol. 2008;38:365-72.
8. Shelley M, Harrison C, Coles B, Staffurth J, Wilt T, Masson M. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006;. doi: 10.1002/14651858.
9. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517-25.
10. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol. 2007;18:1828-33.
11. Iverson P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol. 1997;157:929-34.
12. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int. 2005;75:43-9.
13. Benson RC, Wear JB, Gill GM. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol. 1979;121:452-4.
14. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauv M, Sylvester R. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study (30865). J Urol. 1993;150:1840-4.
15. Elomaa I, Kellokumpu-Lehtinen P, Ranniko S, Alfthan O. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol. 1991;19:12-5.
16. Johansson JE, Andersson SO, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomized study. Br J Urol. 1991;68:67-73.
17. Maier U, Hienert G, Simak R. Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate. Eur Urol. 1990;17:216-8.
18. Soloway MS, deKerinion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol. 1981;125:664-7.
19. Albrecht W, Poppel HV, Horenblas S, Mickisch G, Horwich A, Serreta V, et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer. 2004;90:100-5.
20. Serretta V, Altieri V, Morgia G, Siragusa A, De Grande G, Naopoli M, et al. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. Urol Int. 2009;83:452-7.
21. Perry CM, Mctavish D. Estramusutine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drug Aging. 1995;7:49-74.
22. Hamberg P, Verhagen PCMS, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer. 2008;44:1193-7.